a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10780466		
Filing Date		2004-02-17		
First Named Inventor Kyle I		Marvin et al.		
Art Unit		2191		
Examiner Name	Mary	J. Steelman		
Attorney Docket Number		BEAS-01354US0		

		Remove									
			Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1 6377939 2002-04-23 Young										
	2 6610256 2003-08-02 Barry of al. 3 6609115 2003-98-19 Mehring of al.		Barry et al.								
			Mohring et al.								
	4	6584454	2003-06-24 Hummel et al. 2005-03-29 Murray et al.								
	5	6874143			Murray et al.						
	6	7069507		2006-06-27	Alcazar et al.						
	7	6601113		2003-07-29	Koistinen et al.						
f you wish	to a	dd additional U.S. Pate	nt citatio	If you wish to add additional U.S. Patent citation information please click the Add button.							

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

F

Application Number		10780466
Filing Date		2004-02-17
First Named Inventor	Kyle I	Marvin et al.
Art Unit		2191
Examiner Name Mary		J. Steelman
Attorney Docket Number		BEAS-01354US0

Date Considered

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1	20020083075		2002-06-27		Brummei et al.					
	2	20020184610		2002-12	002-12-05 Chong et al.						
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	please click the Ad	d butto	n. Add		
				FOREIG	3N PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication   Name of Patentee or   Where Re		Pages,Colun where Relevi Passages or Figures Appe	ant Relevant	т	
	1										
If you wisl	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	buttor	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, dity and or country where published.						Ţ5				
	1										
If you wis	h to a	dd additional non-paten	t literatu	re docu	ment cit	ation informat	ion please click the	Add b	utton Add		
				EX	AMINE	R SIGNATUR	E				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature

	Application Number		10780466	
	Filing Date		2004-02-17	
INFORMATION DISCLOSURE	First Named Inventor Kyle I		Marvin et al.	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		2191	
(NOTION SUDMISSION UNDER 37 GFR 1.33)	Examiner Name Mary		J. Steelman	
	Attorney Docket Numb	er	BEAS-01354US0	

See Kind Codes of USPTO Patent Documents at invest ISPTO CDV or MEPF 06104. It is fast office that issued the document, by the No-bitlet code (WIPO Standard ST3). If is chaptenes peared recounters, the indication of the year of the region of the Emperor many precised its sensal number of the patent beautiful processed. If you provide symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark then if Employin Interquals resistation an attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10780466	
Filing Date		2004-02-17	
First Named Inventor Kyle I		Marvin et al.	
Art Unit		2191	
Examiner Name Mary		J. Steelman	
Attorney Docket Numb	er	BEAS-01354US0	

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate	selection(s):
---------------	----------	------------------	-----------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(s)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

on the agracule.							
Signature	/Joseph P. O'Malley/	Date (YYYY-MM-DD)	2007-07-30				
Name/Print	Joseph P. O'Malley	Registration Number	36226				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.